Company news

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news

Sonoma Pharmaceuticals, Inc. news releases on 6ix. Latest, Aug 6, 2026: Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue…

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news

Press releases & updates

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

Sonoma Pharmaceuticals : Annual Report for Fiscal Year Ending 03-31, 2026 (Form 10-K)

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn-based Wound Care Hydrogel

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff

Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results

Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results